Recurrent ovarian cancer

Clinical Advances in Hematology and Oncology

Volumn 3, Issue 9, 2005, Pages 723-736

  Tummala, Mohan K ^a   McGuire, William P ^b,c  

^a UNIVERSITY OF MARYLAND   (United States)

^b Harry and Jeanette Weinberg Cancer Institute   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti neoplastic combined chemotherapy protocols; CA125 antigen; Neoplasm recurrence; Ovarian neoplasm drug therapy; Salvage therapy

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; NAVELBINE; PACLITAXEL; PLATINUM; TAMOXIFEN; TOPOTECAN; TUMOR MARKER; VINBLASTINE; VINCRISTINE;

ABDOMINAL PAIN; ACUTE LEUKEMIA; ALOPECIA; ANEMIA; ARTHRALGIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CAUSE OF DEATH; CLINICAL TRIAL; CONSTIPATION; DRUG CHOICE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FEMALE; FLUID RETENTION; GRANULOCYTOPENIA; GYNECOLOGIC CANCER; HAND FOOT SYNDROME; HUMAN; KIDNEY DYSFUNCTION; LACRIMAL GLAND DISEASE; MONOTHERAPY; MUCOSA INFLAMMATION; MYALGIA; MYELODYSPLASIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PARESTHESIA; PERIPHERAL NEUROPATHY; REVIEW; SALVAGE THERAPY; STOMATITIS; THROMBOCYTOPENIA; UNITED STATES; VOMITING;

ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; CA-125 ANTIGEN; CISPLATIN; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; SALVAGE THERAPY; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 29244435736     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. American Cancer Society web site. http://www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf Accessed August 12, 2005.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
3. Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA. 1983;250:3072-3076.
4. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6.
5. Ozols R, Schwartz P, Eifel P. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita J, Hellman S, Rosenberg S, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins; 2001:1597-1632.
6. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials. N Engl J Med. 1990;322:1021-1027.
7. Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol. 1995;6:887-893.
8. Markman M, Markman J, Webster K, et al. Duration of response to secondline, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004;22:3120-3125 '
9. Rocconi RP, Case AS, Estes JM, Straughn JM Jr, Patridge EE. The role of salvage chemotherapy for platinum-resistant patients with advanced epithelial ovarian cancer: a cost-effective analysis. Paper presented at: Annual Meeting of Society of Gynecologic Oncologists; March 19-23, 2005; Miami Beach, Fla.
10. van der Burg ME, Lammes FB, Verweij J. The role of CA 125 in die early diagnosis of progressive disease in ovarian cancer. Ann Oncol. 1990;1:301-302.
11. Rustin GJ, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996;14:1545-1551.
12. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Ontology Group ancillary report. Gynecol Oncol. 1996;62:4-6.
13. Gordinier ME, Dizon DS, DiSilvestro PA, Moore RS, Weitzen S, Granai CO. Chemotherapy, thalidomide, or treatment holiday for advanced ovarian cancer: a prospective study. Paper presented at: Meeting of the Society of Surgical Gynecologists; March 2005; Miami, Fla.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
15. Gronlund B, Hogdall C, Hilden J, Engelholm SA, Hogdall EV, Hansen HH. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol. 2004;22:4051-4058.
16. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol. 2003;21(suppl 110):s187-s193.
17. Bridgewater JA, Nelstrop AE, Rustin GJ, et al. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol. 1999;17:501-508.
18. Rustin GJ, Nelstrop AE, Crawford M, et al. Phase II trail of oral altretamine for relapsed ovarian carcinoma: Evaluation of defining response by serum CA125. J Clin Oncol. 1997;15:172-176.
19. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist. 2002;7(suppl 5):20-28.
20. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699-708.
21. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON-4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099-2106.
22. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389-393.
23. Gershenson DM, Kavanagh JJ, Copeland LJ, Stringer CA, Morris M, Wharton JT. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy. Obstet Gynecol. 1989;73(5 pt 1):798-802.
24. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 1990;36:207-211.
25. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer. 1989;59:650-653.
26. Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol. 1991;9:1801-1805.
27. McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Ontology Group study. J Clin Oncol. 2000;18:1062-1067.
28. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989;111:273-279.
29. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol. 1994;12:1748-1753.
30. Bolis G, Scarfone G, Giardina G, et al. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol. 2001;81:3-9.
31. Kavanagh J, Tresukosol D, Edwards C, et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol. 1995;13:1584-1588.
32. Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999;17:1141.
33. Rose PG, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritonea] carcinoma. J Clin Oncol. 1998;16:1494-1497.
34. Gronlund B, Hogdall C, Hansen HH, Engelholm SA. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelia] ovarian cancer. Gynecol Oncol. 2001;83:128-134.
35. Cantu MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol. 2002;20:1232-1237.
36. Gonzalez-Martin A, Calvo E, Bover I, Rubio MJ, et al. Randomised phase II study of carboplatin versus paclitaxel-carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma with assessment of quality of life: a GEICO study (Spanish Group for Investigation on Ovarian Carcinoma) [abstract]. Proc Am Soc Clin Oncol. 2003;22:451. A1812.
37. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine/carboplatin vs. carboplatin in platinum sensitive recurrent ovarian cancer: results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. J Clin Oncol. 2004;22(suppl 14S):A5005.
38. Morris RT. Weekly topotecan in the management of ovarian cancer. Gynecol Oncol. 2003;90(3 pt 2):S34-S38.
39. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183-2193.
40. Gore M, ten Bokkel Huinink W, Carmichael J, et al. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol. 2001;19:1893-1900.
41. Vaage J, Donovan D, Mayhew E, Abra R, Huang A. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer. 1993;72:3671-3675.
42. Thierry AR, Dritschilo A, Rahman A. Effect of liposomes on P-glycoprotein function in multidrug resistant cells. Biochem Biophys Res Commun. 1992;187:1098-1105.
43. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-3322.
44. Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1-8.
45. O'Byrne KJ, Bliss P, Graham JD, et al. A phase III study of doxil/caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer. Proc Am Soc Clin Oncol. 2002. Abstract 808.
46. Campos SM, Matulonis UA, Penson RT, et al. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mullerian tumors. Gynecol Oncol. 2003;90:610-618.
47. D'Agostino G, Ferrandina G, Ludovisi M, et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer. 2003;89:1180-1184.
48. Kudelka AP, Tresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996;14:1552-1557.
49. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol. 1996;14:3056-3061.
50. Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol. 1997;66:480-486.
51. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998;16:3345-3352.
52. Cervantes A, Garcia T, Martinez de Duenas E, et al. Phase II trial of liposomal doxorubicin (Caelyx) in relapses of cisplatin refractory ovarian carcinoma [abstract]. Eur J Cancer. 1999;35:S86.
53. Israel VP, Garcia AA, Roman L, et al. Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Gynecol Oncol. 2000;78:143-147.
54. Linardou H, Aravantinos G, Bafaloukos D, et al. Salvage therapy in heavily pretreated ovarian cancer with single agent pegylated liposomal doxorubicin (PLD): preliminary results of a multicentric phase II study of the Hellenic Cooperative Oncology Group [abstract]. Ann Oncol. 2000;11(suppl 4):376P.
55. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol. 2000;78(3 pt 1):369-372.
56. Arcuri C, Sorio R, Lucenti A, et al. A phase II study of Doxil/Caelyx in relapsed epithelial ovarian cancer patients [abstract]. Proc Am Soc Clin Oncol. 2001;20:A2511.
57. Gonzalez de Sande L, Oramas J, Castellano D, et al. Analysis of the efficacy and toxicity of Caelyx in the treatment of heavily pretreated patients with recurrent advanced ovarian cancer: a phase II study [abstract]. Proc Am Soc Clin Oncol. 2001;2O:A881.
58. Sehouli J KI, Kuehne J, et al. Can a biweekly schedule reduce the skin toxicity of pegylated liposomal doxorubicin (PLD)? A phase II study of heavily pretreated patients with recurrent ovarian cancer. Proc Am Soc Clin Oncol. 2003;22:480.
59. Moufarij MA, Phillips DR, Cullinane C. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol Pharmacol. 2003;63:862-869.
60. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 1994; 86:1530-1533.
61. von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. Phase II study of gemcitabine in ovarian cancer. Ann Oncol. 1999;10:853-855.
62. Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol. 1996;63:89-93.
63. Friedlander M, Millward MJ, Bell D, et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian caricer. Ann Oncol. 1998;9:1343-1345.
64. D'Agostino G, Amant F, Berteloot P, Scambia G, Vergote I. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol. 2003;88:266-269.
65. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16:405-410.
66. Eckhardt S, Hernadi Z, Thurzo L, et al. Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer. Results of the South-East European Oncology Group (SEEOG) Study. Oncology. 1990;47:289-295.
67. Markman M, Hakes T, Reichman B, et al. Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. J Cancer Res Clin Oncol. 1992;119:55-57.
68. de Wit R, van der Burg ME, van den Gaast A, Logmans A, Stoter G, Verweij J. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Ann Oncol. 1994;5:656-657.
69. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol. 1994;12:60-63.
70. Bookman MA. Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182). Semin Oncol. 2002;29(suppl 1):20-31.
71. Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol. 1992;30:444-450.
72. Silvestrini R, Zaffaroni N, Orlandi L, Oriana S. In vitro cytotoxic activity of Taxol and Taxotere on primary cultures and established cell lines of human ovarian cancer. Stem Cells. 1993;11:528-535.
73. Untch M, Untch A, Sevin BU, et al. Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. Anticancer Drugs. 1994;5:24-30.
74. Hill BT, Whelan RD, Shellard SA, McClean S, Hosking LK. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs. 1994;12:169-182.
75. Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol. 1994;12:2301-2308.
76. Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer - an updated overview. Eur J Cancer. 1997;33:2167-2170.
77. Piccart MJ, Gore M, ten Bokkel Huinink W, et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst. 1995;87:676-681.
78. Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88:130-135.
79. Markman M, Zanotti K, Webster K, Peterson G, Kulp B, Belinson J. Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecol Oncol. 2003;91:573-576.
80. Kavanagh JJ, Kudelka AP, de Leon CG, et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res. 1996;2:837-842.
81. Markman M. Management of toxicities associated with the administration of taxanes. Expert Opin Drug Saf. 2003;2:141-146.
82. Markman M, Blessing JA, Moore D, Ball H, Lentz SS. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Ontology Group phase II trial. Gynecol Oncol. 1998;69:226-229.
83. Vergote I, Himmelmann A, Frankendal B, Scheistroen M, Vlachos K, Trope C. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol. 1992;47:282-286.
84. Markman M, Hakes T, Reichman B, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol. 1992;10:243-248.
85. Markman M, Kennedy A, Sutton G, et al. Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol Oncol. 1998;70(2):272-274.
86. Rahmani R, Martin M, Barbet J, Cano JP. Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5′-noranhydrovinblastine (navelbine). Cancer Res. 1984;44(12 pt 1):5609-5613.
87. Gershenson DM, Burke TW, Morris M, et al. A phase I study of a daily × 3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol Oncol. 1998;70:404-409.
88. Bajetta E, Di Leo A, Biganzoli L, et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol. 1996;14:2546-2551.
89. Burger RA, DiSaia PJ, Roberts JA, et al. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol. 1999;72:148-153.
90. Sorensen P, Hoyer M, Jakobsen A, Malmstrom H, Havsteen H, Bertelsen K. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol. 2001;81:58-62.
91. George MJ, Heron JF, Kerbrat P, et al. Navelbine in advanced ovarian epithelial cancer: a study of the French oncology centers. Semin Oncol. 1989;16(2 suppl 4):30-32.
92. Rothenberg M, Liu PY, Nahhas W, et al. A phase II trial of vinorelbine in relapsed and refractory ovarian cancar. A southwest Oncology Group study (SWOG-9324). Proc Am Soc Clin Oncol, 1999;18:A1480.
93. Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer. 1991;68:269-271.
94. Ahlgren JD, Ellison NM, Gottlieb RJ, et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic, Oncology Program. J Clin Oncol. 1993;11:1957-1968.
95. Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 2000;18:3093-3100.
96. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997;15:987-993.
97. Rose PG, Maxson JH, Fusco N, Mossbruger K, Rodriguez M. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol. 2001;82:323-328.
98. Kunkel LM, Evans SS, Dottino PR, DiSaia PJ, Nagourney RA, et al. Cisplatin and gemcitabine in relapsed ovarian carcinoma [abstract]. Proc Am Soc Clin Oncol. 1998;17:A1379.
99. Spanu PG, Ferrero AM, Fuse, L, et al. Gemcitabine and vinorelbine in relapsed epithelial ovarian cancer: a phase II study [abstract]. Proc Am Soc Clin Oncol. 2001;20:213a. Abstract 848.
100. Greggi S, Salerno MG, D'Agostino G, et al. Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. Oncology. 2001;60:19-23.
101. Salom E, Mirhashemi N, Lambrou N, Almeida F, Auguste F. Topetecan and doxorubicin HCL liposome combination therapy in the treatment of recurrent/ refractory ovarian cancer: a phase II study [abstract]. 2003;22:476a. Abstract 1911.
102. Voest EE, Verhaar-Langereis MJ. A phase II study of the combination of doxil and topetecan in platinum-resistant ovarian cancer [abstract]. Proc Am Soc Clin Oncol. 2003;22:A2479.
103. Horwood K, Colosimo M, Wyld D, Abraham R, Choo PS, Crandon A. A phase II trial of gemcitabine and liposomal doxorubicin in platinum-resistant ovarian cancer (PROC). Proc Am Soc Clin Oncol. 2001;21;A888.
104. Gallego O, Montesinos J, Losa F, Eres N, Arcusa A. Franquesa R. A phase II study of pegylated liposomal doxorubicin and cyclophosphamide as second line therapy in platinum resistant ovarian cancer patients. Proc Am Soc Clin Oncol. 2003;22:481. Abstract 1931.
105. Oletti MV, Bumma C, Rigault de La Longrais I, et al. Phase II and pharmacokinetic study of liposomal doxorubicin and vinorelbine combination in advanced heavily pretreated epithelial ovarian cancer [abstract]. Proc Am Soc Clin Oncol. 2003;22:A1944.
106. Soh LT, Ho TH. Gemcitabine + cisplatin in patients with paclitaxel and platinum resistant epithelial ovarian cancer. Paper presented at: International Gynecological Cancer Society Meeting; September 26-30, 1999; Rome, Italy.
107. Safra T, Jeffers S, Groshen S, et al. Gemcitabine + amifostine + cisplatin in pretreated epithelial ovarian cancer. Proc Am Soc Clin Oncol. 1999;18:A1481.
108. Velasco A, Perez M, Borrega P, et al. Gemcitabine and cisplatin as treatment for patients with platinum resistant ovarian cancer and as consolidation treatment for patients with residual disease after first line chemotherapy. Proc Am Soc Clin Oncol. 2001;20:2478.
109. Roman L, Garcia AA, Facio G, et al. Phase II study of weekly paclitaxel and gemcitabine in platinum resistant ovarian cancer. Proc Am Soc Clin Oncol. 2001;20;A877.
110. Sehouli J, Lichtenegger W, Hindenburgh HJ, et al. A phase II study of topotecan and gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first line chemotherapy with platin and paclitaxel. Proc Am Soc Clin Oncol. 2001;20:A861.